Sentences with phrase «of acute myelogenous leukemia»

A 64 - year - old male with history of Acute Myelogenous Leukemia (AML) status post bone marrow transplant (BMT) in complete remission presented with dyspnea when laying on his right side which resolved when supine or in the left lateral decubitus position.

Not exact matches

It is activated in 50 to 80 percent of patients with acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations.

In both acute and chronic myelogenous leukemia, immature white blood cells in the bone marrow multiply out of control.

[3]-RRB- However, the presence of the Philadelphia (Ph) chromosome is not sufficiently specific to diagnose CML, since it is also found in acute lymphoblastic leukemia [4](aka ALL, 25 — 30 % of adult cases and 2 — 10 % of pediatric cases) and occasionally in acute myelogenous leukemia (AML).

A Phase I Study of DS - 3201B in Subjects with Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

There was scant experimental evidence for this hypothesis until 1994, when John Dick and colleagues demonstrated that leukemia - initiating stem cells (LSCs) present in the blood of leukemia patients may induce acute myelogenous leukemia (AML) when transplanted into severe combined immunodeficient mice (2).

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF - kappaB pathway and generation of reactive oxygen species.

May 30, 2015 Khoury et al ASCO AST - VAC1 Presentation Long - term Follow - up of Patients with Acute Myelogenous Leukemia Receiving an Autologous Telomerase - based Dendritic Cell Vaccine

Autologous HCT is used primarily for the treatment of diseases such as lymphoma, Hodgkin disease, acute myelogenous leukemia, myeloma, breast cancer and testicular cancer.

These mutant kinases are attractive therapeutic targets, as demonstrated by the efficacy of imatinib in BCR - ABL — positive chronic myelogenous leukemia (CML), 5 as well as in MPD associated with activating alleles involving PDGFRA or PDGFRB.2, 6,7 In addition, activating mutations in the FLT3 receptor tyrosine kinase are the most common genetic event in acute myeloid leukemia (AML), and specific inhibitors of the FMS - like tyrosine kinase 3 (FLT3) have entered late - stage clinical trials.8 Although mutations in tyrosine kinases and in other genes have been identified in a subset of MPD and AML, in many cases the genetic events that contribute to the molecular pathogenesis of these diseases remain unknown.

ONC201 demonstrated (GI50 1 - 8 µM) dose - and time - dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B - cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T - cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples.

he study reiterates earlier research which shows that prolonged exposure to airborne petroleum hydrocarbons causes «an increased risk of eye irritation and headaches, asthma symptoms, acute childhood leukemia, acute myelogenous leukemia, and multiple myeloma.»